** SkyePharma dives to lowest levels in more than 4mths on lower-than-expected GlaxoSmithKline Q3 2014sales of Relvar/Breo Ellipta and Anoro Ellipta, which both useSkyePharma licensed technology [ID:
** Stock, which has had great run over the past year, risingaround 200 pct, down 16.5 pct & poised for worst one-day pctmove since June 2010
** Co says royalties should still reach the cap of 9 mln stga year, but this may be one year later than it previouslyexpected
** Also, co spokesman says market caught off-guard bySkyePharma saying it will spend more on R&D of new products;says co will have to explain to investors what it is going toinvest money on in more detail
(RM:richa.naidu.thomsonreuters.com@reuters.net)
